Over the course of his career, Dr. Patrick Soon-Shiong invented and developed the revolutionary drug Abraxane, which has received FDA approval for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer. He has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 170 issued patents worldwide on groundbreaking advancements spanning myriad fields of technology and medicine.
As part of his commitment to improve healthcare, Dr. Soon-Shiong formed NantWorks, an umbrella organization that oversees multiple companies and breakthrough technology platforms looking to integrate cloud computing, genomic analysis and targeted drug development to turn cancer into a manageable disease. He also announced the formation of Cancer Breakthroughs 2020, a comprehensive collaboration of researchers, insurers and pharmaceutical companies that seeks to accelerate the potential of combined immunotherapy in the treatment of cancer.
Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
Dr. Soon-Shiong has received numerous honors, including the Franklin Institute Award, the 2016 Pontifical Key Visionary Award, and the Distinguished Medical Science Award from the National Library of Medicine.